Couverture de Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs)

Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs)

Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs)

De : Annenberg Center for Health Sciences
Écouter gratuitement

À propos de cette écoute

 Immune checkpoint inhibitors (ICIs) have transformed oncology but IV administration can cause infusion reactions, require line access, and add staff and chair-time burden. Recently, atezolizumab and nivolumab were approved for subcutaneous use, with more in development. In this podcast, oncologists Lucio Gordan, MD, and Saby George, MD, discuss the burden of IV ICIs, how subcutaneous options address these issues, compare efficacy and safety, and highlight the role of multidisciplinary teams in treatment decisions and workflow optimization.Annenberg Center for Health Sciences
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Summary of Key Concepts

      Summary of Key Concepts
      Jul 31 2025
      • Subcutaneous ICI products may offer significant time savings for patients, caregivers, and health care facilities with shorter compounding, administration, and chair time
      • With multiple ICI therapies now approved for subcutaneous injection and more under development, it is vital for institutions to develop interprofessional/multidisciplinary approaches and workflows to integrate novel therapies


      Afficher plus Afficher moins
      8 min
    • Interprofessional, Multidisciplinary Collaboration Strategies for Novel Immune-Checkpoint Inhibitor Delivery Systems

      Interprofessional, Multidisciplinary Collaboration Strategies for Novel Immune-Checkpoint Inhibitor Delivery Systems
      Jul 31 2025
      • SC products offer convenient and safe options for patients that may be preferred by patients
      • Effective communication among interprofessional, multidisciplinary team and patients/caregivers is crucial to success and streamlining processes
      • Training is required for providers and staff related to operational, clinical, and financial considerations of SC products
      Afficher plus Afficher moins
      23 min
    • Treatment Strategies with ICIs (Efficacy and Safety Data for SC Products)

      Treatment Strategies with ICIs (Efficacy and Safety Data for SC Products)
      Jul 30 2025
      • Atezolizumab and nivolumab are both FDA approved as SC products (pembrolizumab pending approval)
      • Overall safety and efficacy of SC ICI products are similar to IV ICI counterpart therapies
      • Patients receiving SC ICI may experience mild injection site reactions
      • Clinical guidelines (NCCN) recommend
      Afficher plus Afficher moins
      8 min
    Aucun commentaire pour le moment